Peters曾于1970年提出,萘醌衍生物——环辛醌和环氯胍对抗血液接种小鼠伯氏疟原虫有一种新的增效现象,而此种现象,在同样条件时,未在环辛醌与乙胺嘧啶的合并用药中发现。鉴于新型的羟基萘醌类化合物——2-(4-叔丁基环己基)-3-羟基-1,4-萘醌(BW58C)有相当好的抗疟原虫作用,故测定了BW58C和二氢叶酸还原酶抑制剂合并 Peters proposed in 1970 that naphthoquinone derivatives -cycloxinquinone and cyclazocine had a new synergistic effect against blood-borne P. berghei, and this phenomenon, under the same conditions, was not observed in the ring Xin quinone and pyrimethamine combination medication found. In view of the relatively good anti-malarial effect of the novel hydroxynaphthoquinone compound 2- (4-tert-butylcyclohexyl) -3-hydroxy-1,4-naphthoquinone (BW58C), BW58C and dihydrofolic acid Reductase inhibitors are combined